Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
AURO LAB. TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AURO LAB. Mar-23 |
TEVA PHARMA Dec-13 |
AURO LAB./ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 116 | 3,483 | - | |
Low | Rs | 53 | 3,026 | - | |
Sales per share (Unadj.) | Rs | 84.9 | 1,998.8 | - | |
Earnings per share (Unadj.) | Rs | 3.9 | 124.9 | - | |
Cash flow per share (Unadj.) | Rs | 5.6 | 286.4 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.31 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 54.9 | 2,220.3 | - | |
Shares outstanding (eoy) | m | 6.23 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.0 | 1.6 | 61.0% | |
Avg P/E ratio | x | 21.5 | 26.1 | 82.5% | |
P/CF ratio (eoy) | x | 14.9 | 11.4 | 131.4% | |
Price / Book Value ratio | x | 1.5 | 1.5 | 104.7% | |
Dividend payout | % | 0 | 87.5 | 0.0% | |
Avg Mkt Cap | Rs m | 525 | 2,759,528 | 0.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 38 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,712.8 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,355.9 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 529 | 1,695,000 | 0.0% | |
Other income | Rs m | 9 | 0 | - | |
Total revenues | Rs m | 538 | 1,695,000 | 0.0% | |
Gross profit | Rs m | 44 | 464,177 | 0.0% | |
Depreciation | Rs m | 11 | 137,008 | 0.0% | |
Interest | Rs m | 8 | 33,293 | 0.0% | |
Profit before tax | Rs m | 34 | 293,876 | 0.0% | |
Minority Interest | Rs m | 0 | 1,335 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,913 | -0.0% | |
Tax | Rs m | 10 | -3,588 | -0.3% | |
Profit after tax | Rs m | 24 | 105,885 | 0.0% | |
Gross profit margin | % | 8.3 | 27.4 | 30.3% | |
Effective tax rate | % | 29.1 | -1.2 | -2,385.7% | |
Net profit margin | % | 4.6 | 6.2 | 73.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 354 | 1,144,797 | 0.0% | |
Current liabilities | Rs m | 181 | 998,360 | 0.0% | |
Net working cap to sales | % | 32.6 | 8.6 | 377.4% | |
Current ratio | x | 2.0 | 1.1 | 170.2% | |
Inventory Days | Days | 2 | 91 | 2.5% | |
Debtors Days | Days | 85,599 | 96 | 89,246.9% | |
Net fixed assets | Rs m | 206 | 553,624 | 0.0% | |
Share capital | Rs m | 62 | 4,172 | 1.5% | |
Net worth | Rs m | 342 | 1,882,824 | 0.0% | |
Long term debt | Rs m | 20 | 866,691 | 0.0% | |
Total assets | Rs m | 560 | 3,873,619 | 0.0% | |
Interest coverage | x | 5.2 | 9.8 | 53.3% | |
Debt to equity ratio | x | 0.1 | 0.5 | 12.8% | |
Sales to assets ratio | x | 0.9 | 0.4 | 215.9% | |
Return on assets | % | 5.8 | 3.6 | 161.9% | |
Return on equity | % | 7.1 | 5.6 | 127.0% | |
Return on capital | % | 11.8 | 4.9 | 238.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 33 | 270,095 | 0.0% | |
From Investments | Rs m | -51 | -95,706 | 0.1% | |
From Financial Activity | Rs m | -82 | -323,998 | 0.0% | |
Net Cashflow | Rs m | -100 | -149,608 | 0.1% |
Compare AURO LAB. With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare AURO LAB. With: SHAMROCK IND MAKERS LAB. HIKAL. PHARMAIDS PH SUVEN PHARMACEUTICALS
After opening the day on positive note, Indian share markets reversed the trend as the session progressed and ended lower.